Sonnet Received Approval Of Its Application To Sell Up To $8,143,144 Of Its New Jersey State Net Operating Losses And $62,810 Of Its New Jersey State R&D Tax Credits For Proceeds Of Up To $0.795M Through The New Jersey Technology Business Tax...
Sonnet Received Approval Of Its Application To Sell Up To $8,143,144 Of Its New Jersey State Net Operating Losses And $62,810 Of Its New Jersey State R&D Tax Credits For Proceeds Of Up To $0.795M Through The New Jersey Technology Business Tax...
The Australian R&D Tax Incentive Program allows certain companies to claim a significant percentage of their costs related to R&D activities they have or are planning to undertake in Australia.Sonnet Received Approval Of Its Application To Sell Up To $8,143,144 Of Its New Jersey State Net Operating Losses And $62,810 Of Its New Jersey State R&D Tax Credits For Proceeds Of Up To $0.795M Through The New Jersey Technology Business Tax Certificate Transfer Program; Also Expects To Receive A $0.7M Net Cash Refund From The R&D Tax Incentive Program In Australia
Sonnet獲批准，可通過新澤西州技術業務稅證書轉讓計劃出售高達814.3144百萬美元的新澤西州淨經營虧損和62810美元的新澤西州研發稅收抵免，以獲得高達79.5萬美元的收益；同時也預計從澳洲研發稅激勵計劃中獲得70萬美元的淨現金退款。
Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced it has received preliminary approval for a tax credit from the New Jersey Technology Business Tax Certificate Transfer Program administered by the New Jersey Economic Development Authority (NJEDA). Sonnet received approval of its application to sell up to $8,143,144 of its New Jersey State net operating losses (NOLs) and $62,810 of its New Jersey State research and development (R&D) tax credits for proceeds of up to $0.795 million through the New Jersey Technology Business Tax Certificate Transfer Program, subject to execution of such sale. Sonnet also expects to receive a $0.7 million net cash refund from the R&D Tax Incentive Program in Australia.
Sonnet生物製藥控股公司（"公司"或"Sonnet"）（NASDAQ:SONN），一家開發靶向免疫治療藥物的臨床階段公司，今天宣佈已獲得新澤西州經濟發展局（NJEDA）管理的新澤西州技術業務稅證書轉讓計劃的稅收抵免初步批准。Sonnet獲准出售高達814.3144百萬美元的新澤西州淨經營虧損（NOL）和62810美元的新澤西州研究與開發（R＆D）稅收抵免，以獲得高達79.5萬美元的收益，前提是要執行此類銷售。Sonnet還預計將從澳大利亞研發稅激勵計劃獲得70萬美元的淨現金退款。
Pankaj Mohan, Founder and Chief Executive Officer of Sonnet commented, "We are grateful for NJEDA's continued support of the biotechnology industry and to be one of the recipients to benefit from the New Jersey Technology Business Tax Certificate Transfer Program. With the addition of the net cash refund from the Australian R&D Tax Incentive Program, this will provide Sonnet with non-dilutive capital to continue to direct our resources towards advancing our pipeline of targeted immunotherapeutic drugs."
Sonnet創始人兼首席執行官Pankaj Mohan評論說：「感謝NJEDA對生物技術行業的持續支持，並且很榮幸成爲受益於新澤西州技術業務稅證書轉讓計劃的受益者之一。加上來自澳大利亞研發稅激勵計劃的淨現金退款，這將爲Sonnet提供非稀釋性資本，以繼續將我們的資源投向推進靶向免疫治療藥物的管線。」
The Technology Business Tax Certificate Transfer Program administered by the NJEDA enables qualified companies to sell up to $20 million of their unused New Jersey NOLs and R&D tax credits to unaffiliated, profit-generating corporate taxpayers in the State of New Jersey. The Technology Business Tax Certificate Transfer Program is designed to allow technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund more R&D, expand its workforce and cover other allowable expenditures. Sonnet is one of several biotechnology/technology companies to qualify in this competitive process to share in the funding this year.
由NJEDA管理的技術業務稅證書轉讓計劃使合格公司能夠將其未使用的新澤西州淨經營虧損和研發稅收抵免高達2000萬美元出售給新澤西州的非關聯、盈利的公司納稅人。技術業務稅證書轉讓計劃旨在允許擁有淨經營虧損的技術和生物技術公司將其納稅虧損和抵免轉化爲現金收入，以資助更多的研發、擴大其員工隊伍和支付其他可允許的支出。Sonnet是今年在這一競爭激烈的過程中有資格分享這一資金的幾家生物技術/技術公司之一。
The Australian R&D Tax Incentive Program allows certain companies to claim a significant percentage of their costs related to R&D activities they have or are planning to undertake in Australia.
澳洲研發稅收優惠計劃允許某些公司申報與他們在澳洲進行的或計劃進行的研發活動相關的成本的顯着比例。
The Company expects to receive the Australian net cash refund before calendar year end 2024 and the proceeds from the sale of its New Jersey NOLs and R&D tax credits before the end of the first calendar quarter of 2025, subject to execution of such sale.
公司預計將在2024年日曆年結束前收到澳洲淨現金退款，並預計在2025年第一季度日曆季度結束前收到來自新澤西州NOLs和研發稅收抵免銷售所得，前提是執行此類銷售。
譯文內容由第三人軟體翻譯。
